[Retracted] The Number of Intraoperative Intestinal Venous Circulating Tumor Cells Is a Prognostic Factor for Colorectal Cancer Patients

Table 1

The association between IVB CTC counts and patient clinicopathological findings.

Variations	N	Positive/negative	CTCs-positive (%)	χ^2	P-value
Gender				1.446	0.229
Male	108	87/21	80.56
Female	54	39/15	72.22
Age/years				0.177	0.674
≤60	77	61/16	79.22
>60	85	65/20	76.47
Tumor location				0.604	0.739
Left colon	41	32/9	78.04
Right colon	61	37/14	52.46
Rectum	60	47/13	78.33
Histologic differentiated				1.990	0.370
Poorly	51	41/10	80.39
Moderately	107	83/24	77.57
Well	4	2/2	50.00
Diameter/cm				2.105	0.147
≤4.0	57	48/9	84.21
>4.0	105	78/27	74.29
Invasion depth				2.066	0.151
T1-T2	42	36/6	85.71
T3-T4	120	90/30	75.00
Lymph node metastasis				0.231	0.630
Negative	150	116/34	77.33
Positive	12	10/2	83.33
TNM staging				12.091	0.002
I	37	31/6	83.78
II	87	59/28	67.82
III	38	36/2	94.74
AFP (ng/ml)				1.070	0.301
≤7.0	110	83/27	75.45
>7.0	52	43/9	82.69
CEA (ng/ml)				0.458	0.498
≤5.2	91	69/22	75.82
>5.2	71	57/14	80.28
CA19-9 (U/ml)				0.007	0.933
≤27	71	55/16	77.46
>27	91	71/20	78.02
CA-125 (U/ml)				50.968	0.000
≤35	58	27/31	46.55
>35	104	99/5	95.19
>35	104	99/5	95.19
CA72-4 (U/ml)				0.270	0.604
≤6.9	44	33/11	75.00
>6.9	118	93/25	78.81

CTCs, circulating tumor cells; AFP, alpha-fetoprotein; CEA, carcinoembryonic antigen; CA19-9, glycoprotein antigen 199; CA-125, glycoprotein antigen 125; CA72-4, glycoprotein antigen 72-4.